A partner in Goodwin’s Technology group, Michael McGrail’s practice includes the representation of company and investor clients in a full range of corporate legal projects, including mergers and acquisitions, private financings, corporate partnerships, and technology licensing. He counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. Michael is fluent in German, and a significant portion of his practice is devoted to international transactions.
Experience
M&A Transactions:
- Represented Tillotts in its joint venture with TVM Capital Life Science*
- Represented Baylis in its acquisition by Boston Scientific*
- Represented BASF in its acquisition of Becker Underwood*
- Represented TYRX in its acquisition by Medtronic*
- Represented HyperBranch Medical Technology in its acquisition by Stryker*
- Represented Image Stream Medical in its acquisition by Olympus*
- Represented Impact Instrumentation is its acquisition by ZOLL Medical*
- Represented SuppreMol in its acquisition by Baxter*
- Represented Carl Zeiss in a strategic collaboration with, and ultimate acquisition of, Oraya Therapeutics*
- Represented Entellus Medical in its acquisition of CogENT Therapeutics assets*
- Represented Urban Decay in its acquisition by L’Oreal*
- Represented SVOX in its acquisition by Nuance*
Venture Financings:
- Represented PartsTech in connection with its $35m Series C financing*
- Represented General Catalyst in its Series B investment in Helsing*
- Represented Casana Health in its $30m Series B Preferred Stock Financing*
- Represented argenx BV in its investment in OncoVerity*
- Represented Podimetrics in its $45m Series C Preferred Stock Financing*
- Represented Luminopia in its $16m Series A Preferred Stock Financing*
- Represented VideaHealth in its $20m Sereis A Preferred Stock Financing*
- Represented Probably Genetic in its $11m Series A Preferred Stock Financing*
- Represented InGeneron in its $43m Series D Preferred Stock Financing*
- Represented Melodi Health in its $10m Series A Preferred Stock Financing*
- Represented BASF in a $50m equity investment and collaboration with Sion Power*
- Represented Allianz in Lemonade’s $300m Series D Preferred Stock Financing*
- Represented Allianz in its $58m preferred stock investment in American Well*
*Denotes experience prior to joining Goodwin
Professional Experience
Prior to joining Goodwin, Michael was a partner at Cooley.
Credentials
Education
JD2001
Boston College Law School
BA1993
Northeastern University
Admissions
Bars
- Massachusetts